Vyome (HIND)
Develops topical therapies for inflammatory conditions and cancer-wound symptoms.
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #VT1953--Vyome Holdings, Inc. (NASDAQ: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, announces that the China National Intellectual Property Administration (CNIPA) has granted a patent (Chinese Patent No. ZL 2021 1 0758695.X) covering formulation and therapeutic use claims relating to its proprietary besifloxacin topical gel program for infl.
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Holdings, Inc. (Nasdaq: HIND)(âVyomeâ), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said, “Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical need focused on.
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (“Impetis”), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Janus kinase (JAK) inhibitors are immunomodulatory drugs that treat autoimmune and inflammatory conditions by blocking JAK enzymes. Several JAK inhibitors are FDA-approved to treat a wid.
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds (“MFW”) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome,.
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program. Key anticipated benefits of an orphan drug designation include 7 years of U.S. market exclusivity, up to 25% of tax credits on clinical trials conducted in the USA, exemption from FDA Prescrip.
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.
Vyome (NASDAQ:HIND) versus Medline (NASDAQ:MDLN) Critical Review
Medline (NASDAQ: MDLN - Get Free Report) and Vyome (NASDAQ: HIND - Get Free Report) are both manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk. Earnings and Valuation This table compares Medline and Vyome"s revenue,
Vyome (NASDAQ:HIND) & Medline (NASDAQ:MDLN) Critical Analysis
Vyome (NASDAQ: HIND - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Earnings and Valuation This table compares Vyome and Medline"s gross
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome VT-1953 P2 results.
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome's lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026. “I am excited to work with Vyome team and.
Vyome Holdings Announces Results of Annual Shareholder Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Annual meeting of Vyome Holdings Inc.
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1). Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States.
Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio
CAMBRIDGE, Mass. & PUNE, India--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an MoU (Memorandum of Understanding) to jointly pursue the global AI-enabled medical device market. This partnership will combine Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to potentially productize and commercialize smart medical devices that can transfo.